Montreux Equity Partners
   
 

Latest News

June 19, 2008
Cerexa/Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections

May 12, 2008
Novalar Receives FDA Approval for OraVerse™

January 3, 2008
Montreux Equity Partners Closes $250 Million MEP IV Life Sciences Fund

November 7, 2007
ARYx Therapeutics, Inc. Announces Pricing of its Initial Public Offering



Action. Experience. Collaboration.

Montreux Equity Partners is a life sciences venture capital firm focused on building great pharmaceutical and medical device companies. Montreux's goal is to generate significant returns by investing in superior businesses with high quality management teams.

Montreux seeks investment opportunities in which it can add value beyond the commitment of capital. Montreux works with entrepreneurs and management teams who wish to operate in a dynamic partnership based on shared interests and common goals. Montreux's operating philosophy is anchored in a foundation of honesty, integrity, and uncompromising professionalism.

©2008 Montreux Equity Partners. All Rights Reserved.